Darolutamide
Highest phase reached
Approved
Drug type
Small molecule
First approval year
2019
- First approval year
- 2019
- Listing at source
- Listed
- Highest phase reached
- Approved
- Drug type
- Small molecule
- Drug name
- Darolutamide
- Molecular weight
- 398.85
- Structure (SMILES)
- CC(O)c1cc(C(=O)N[C@@H](C)Cn2ccc(-c3ccc(C#N)c(Cl)c3)n2)n[nH]1
- nubeqa
- Nubeqa
- bay 1841788
- BAY 1841788
- bay 1841788 odm 201
- BAY 1841788(ODM-201)
- BAY-1841788
- bay1841788
- BAY1841788
- BAY1841788 (darolutamide)
- BAY1841788 (ODM-201)
- darolutamida
- Darolutamida
- darolutamide
- Darolutamide
- Darolutamide (BAY 1841788)
- Darolutamide (BAY1841788)
- Darolutamide (Nubeqa®) 300 mg tablets
- darolutamide [INN]
- DAROLUTAMIDE [JAN]
- DAROLUTAMIDE [MI]
- DAROLUTAMIDE [ORANGE BOOK]
- DAROLUTAMIDE [USAN]
- Darolutamide [WHO-DD]
- Darolutamide 300 mg
- darolutamide inn
- darolutamide jan
And 11 more, listed on the interactive page.
- CAS registry numbers
- 1297538-32-9
- ChEMBL ID
- CHEMBL4297185
- InChIKey
- BLIJXOOIHRSQRB-PXYINDEMSA-N
- PubChem compound IDs
- 67171867
- RxNorm IDs (RxCUI)
- 2180325
- FDA ingredient codes (UNII)
- X05U0N2RCO
- L02BB
- L02BB06
Sources for recorded values
- Applicant
- BAYER HEALTHCARE
- Approval date
- 30 Jul 2019
- Application number
- NDA212099
- Status
- Authorised
- Status date
- 27 Mar 2020
- Authorisation date
- 27 Mar 2020
- Approved indications
- NUBEQA is indicated for the treatment of adult men with non‑metastatic castration resistant prostate cancer (nmCRPC) who are at high risk of developing metastatic disease (see section 5.1). metastatic hormone‑sensitive prostate cancer (mHSPC) in combination with androgen deprivation therapy (see section 5.1). metastatic hormone‑sensitive prostate cancer (mHSPC) in combination with docetaxel and androgen deprivation therapy (see section 5.1).
- Product number
- EMEA/H/C/004790
- Authorisation holder
- Bayer AG
- Priority medicines scheme
- No
- Generic
- No
- Biosimilar
- No
- Generic medicines
- 0
- Biosimilar medicines
- 0
- Advanced therapy
- No
- Conditional approval
- No
- Additional monitoring
- No
- Accelerated assessment
- No
- Exceptional circumstances
- No
Therapeutic areas
- Prostatic Neoplasms, Castration-Resistant
European medicines record
- Patents
- 9
- Designations
- 2
- Earliest recorded loss of exclusivity
- 17 Jun 2042
- First in class
- No
- Fast track
- Yes
- Breakthrough designation
- No
- Orphan designation
- No
- Priority review
- Yes
- Orphan exclusivity
- No
- Accelerated approval
- No
- Availability
- Prescription only
- Pharmacology name
- darolutamide
- Type
- Synthetic organic
- Drug name stem
- -lutamide
- Approval recorded by Guide to Pharmacology
- Yes
Administration routes
- Oral
- Action
- Antagonist
- Action type
- Antagonist
- Target
- Androgen receptor
- Gene symbol
- AR
- Protein identifier
- P10275
- Median affinity
- 7.59
- Affinity units
- pIC50
- Primary target
- Yes
- Mechanism
- Androgen Receptor antagonist
- Action type
- Antagonist
- Target
- Androgen receptor
- Protein identifier
- P10275
Open Targets mechanisms
- Mechanism
- Androgen Receptor antagonist
- Action type
- Antagonist
- Target
- Androgen receptor
- Action type
- Antagonist
- Gene symbol
- PGR
- Protein identifier
- P06401
- Organism
- Homo sapiens
- Target development level
- Clinical
- Action type
- Inhibitor
- Gene symbol
- AR
- Protein identifier
- P10275
- Organism
- Homo sapiens
- Target development level
- Clinical
- Condition
- Prostatic Neoplasms
- Highest recorded phase
- 4
- Condition identifier
- EFO:0000196
- Subject identifier
- D011471
- Condition
- Neoplasms
- Highest recorded phase
- 4
- Condition identifier
- EFO:0000616
- Subject identifier
- D009369
- Condition
- Prostatic Neoplasms
- Highest recorded phase
- 4
- Condition identifier
- EFO:0000673
- Subject identifier
- D011471
- Condition
- Prostatic Neoplasms
- Highest recorded phase
- 4
- Condition identifier
- EFO:0001663
- Subject identifier
- D011471
- Condition
- Salivary Gland Neoplasms
- Highest recorded phase
- 2
- Condition identifier
- MONDO:0000521
- Subject identifier
- D012468
- Condition
- Salivary Gland Neoplasms
- Highest recorded phase
- 2
- Condition identifier
- MONDO:0004669
- Subject identifier
- D012468
- Condition
- Neoplasms
- Highest recorded phase
- 4
- Condition identifier
- MONDO:0004992
- Subject identifier
- D009369
- Condition
- Breast Neoplasms
- Highest recorded phase
- 2
- Condition identifier
- MONDO:0007254
- Subject identifier
- D001943
- Condition
- Prostatic Neoplasms
- Highest recorded phase
- 4
- Condition identifier
- MONDO:0008315
- Subject identifier
- D011471
- Condition
- Prostatic Neoplasms, Castration-Resistant
- Highest recorded phase
- 4
- Condition identifier
- MONDO:0008315
- Subject identifier
- D064129
- Condition
- Granulosa Cell Tumor
- Highest recorded phase
- 2
- Condition identifier
- MONDO:0020541
- Subject identifier
- D006106
- Condition
- Prostatic Neoplasms, Castration-Resistant
- Highest recorded phase
- 4
- Condition identifier
- MONDO:0021259
- Subject identifier
- D064129
- Condition identifier
- EFO_0000196
- Highest recorded phase
- 3
- Condition identifier
- EFO_0000616
- Condition identifier
- EFO_0000673
- Highest recorded phase
- 3
- Condition identifier
- EFO_0001663
- Highest recorded phase
- 3
- Condition identifier
- EFO_0006461
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0000521
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0004669
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0004956
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0004992
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0004992
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0005070
- Highest recorded phase
- 4
- Condition identifier
- MONDO_0005082
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0005233
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0005494
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0007254
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0008315
- Condition identifier
- MONDO_0008315
- Highest recorded phase
- 4
- Condition identifier
- MONDO_0020541
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0021259
- Condition identifier
- MONDO_0023283
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0044881
- Highest recorded phase
- 1
- Event
- brainstem compression
- Reports
- 1
- Reporting signal score
- 8.64902
- Event
- fatigue
- Reports
- 22
- Reporting signal score
- 13.1482
- Event
- gastric cancer recurrent
- Reports
- 1
- Reporting signal score
- 5.8774
- Event
- hormone-refractory prostate cancer
- Reports
- 7
- Reporting signal score
- 39.6865
- Event
- hospitalisation
- Reports
- 11
- Reporting signal score
- 14.2687
- Event
- malignant neoplasm of renal pelvis
- Reports
- 1
- Reporting signal score
- 5.48603
- Event
- metastases to bone
- Reports
- 4
- Reporting signal score
- 9.31887
- Event
- nothing by mouth order
- Reports
- 1
- Reporting signal score
- 7.39642
- Event
- parvovirus b19 test positive
- Reports
- 1
- Reporting signal score
- 5.97574
- Event
- product dose omission issue
- Reports
- 5
- Reporting signal score
- 6.23357
- Event
- prostatic specific antigen increased
- Reports
- 6
- Reporting signal score
- 18.9081
- Event
- stoma obstruction
- Reports
- 1
- Reporting signal score
- 5.62241
- NCT01317641
- NCT01429064
- NCT01784757
- NCT02200614
- NCT02799602
- NCT02933801
- NCT02972060
- NCT03385655
- NCT03568656
- NCT03724747
- NCT03903835
- NCT04025372
- NCT04136353
- NCT04157088
- NCT04176081
- NCT04237584
- NCT04558866
- NCT04737109
- NCT04916613
- NCT05059236
- NCT05116475
- NCT05171387
- NCT05249712
- NCT05346848
- NCT05348876
And 35 more, listed on the interactive page.
- Dose
- 600 mg
- Route
- Oral
- How often
- Twice daily
- Swallow tablets whole
- Take with food
- Hydrogen bond acceptors
- 6
- Hydrogen bond donors
- 3
- Polar surface area
- 119.62
- Calculated partition coefficient (ALogP)
- 2.67
- Calculated partition coefficient (XLogP)
- 1.8
- Prodrug
- No
- Chirality
- Racemic
- Inorganic
- No
- Rule-of-five violations
- 0
- Rotatable bonds
- 6
- Heavy atoms
- 28
- Molecular formula
- C19H19ClN6O2
- Monoisotopic mass
- 398.1258016
- Natural product
- Yes
- 50419-395
- Recorded assays
- 288
- Active assays
- 26
Active assay types
- Confirmatory
Solubility
- Median
- 24,460
- Mean
- 24,460
- Minimum
- 24,460
- Maximum
- 24,460
- Unit
- nM
- Assays
- 1
- Standard deviation
- 0
- Summary method
- median
- Censored results excluded
- 0
- Other units excluded
- 0
- Unknown units excluded
- 0
Measurement types
- Solubility
Related records
Trials (120)
- 177Lu-PSMA-617 Combined With Darolutamide in Neoadjuvant Treatment of High-risk Localized Prostate Cancer: a Prospective, Single-arm, Multi-center Clinical Trial
- A Clinical Study of KTX-2001 in Subjects With Metastatic Castration-Resistant Prostate Cancer (STRIKE-001)
- A Phase 1b/2a Study of Pocenbrodib as Monotherapy and in Combination With Darolutamide in Participants With mCRPC
- A Phase 2 Trial of Darolutamide as a Prostate-Specific Membrane Antigen (PSMA) Expression Enhancer in Patients With Localized Prostate Cancer
- A Phase II Neoadjuvant Study of Darolutamide Plus ADT in Men With Localized Prostate Cancer
- A Study Called ARAMON to Learn to What Extent Does Study Treatment With Darolutamide Affects Testosterone Levels in Men With Prostate Cancer That Had Not Been Treated With Hormonal Therapy Compared to Treatment With Enzalutamide
- A Study Comparing ARB With Radium-223 vs ARB Therapy With Placebo and the Effect Upon Survival for mCRPC Patients
- A Study in Which Non-metastatic Castration-resistant Prostate Cancer (nmCRPC) Patients for Whom a Decision to Treat With Darolutamide Has Been Made Before Enrollment Are Observed and Certain Outcomes Are Described
- A Study of HRS-5041 Tablets Combined With Antitumor Therapy in Subjects With Advanced Prostate Cancer
- A Study of Pasritamig (JNJ-78278343) in Combination With Other Agents for Metastatic Prostate Cancer
- A Study of Patient Preference Between ODM-201 and Enzalutamide in Men With Metastatic Castrate-resistant Prostate Cancer
- A Study of Valemetostat (DS-3201b) in Combination With Darolutamide in Metastatic Castration Resistant Prostate Cancer (mCRPC)
- A Study to Compare Darolutamide Given With Androgen Deprivation Therapy (ADT) and Placebo Given With ADT in Men With Hormone Sensitive Prostate Cancer and Raise of Prostate Specific Antigen (PSA) Levels After Local Therapies
- A Study to Evaluate Changes in Human Breast Cancer Tissue Following Short-Term Use of Darolutamide
- A Study to Investigate the Biological Effects of Saruparib (AZD5305), Darolutamide, and in Combination in Men With Newly Diagnosed Prostate Cancer.
- A Study to Learn About How Safe Darolutamide is and How Well it Works in Combination With Androgen Deprivation Therapy and Docetaxel in Routine Medical Care for Japanese Men With Low Volume Metastatic Hormone-Sensitive Prostate Cancer
- A Study to Learn About Real-world Utilization and Outcomes of Darolutamide and Other Androgen Receptor Pathway Inhibitors (ARPIs) for Newly Diagnosed Metastatic Hormone-sensitive Prostate Cancer (de Novo mHSPC) in US Urology Clinics
- A Study to Learn About the Investigational Drug Rinzimetostat (ORIC-944) in Patients With mCRPC Who Were Previously Treated With Abiraterone Acetate (Himalayas-1)
- A Study to Learn About the Outcomes Between Study Medicines, Enzalutamide and Darolutamide Among Men With Metastatic Castration Sensitive Prostate Cancer (mCSPC)
- A Study to Learn How Men With Advanced Prostate Cancer Respond to Treatment With Darolutamide and Hormone Therapy, With or Without Chemotherapy, in Real-world Medical Practice
Approved for (7)
- Cancer
- Metastatic prostate carcinoma
- Neoplasm
- Prostate adenocarcinoma
- Prostate cancer
- Prostate carcinoma
- Prostate neoplasm
In development for (4)
- Breast cancer Phase 2
- Maligant granulosa cell tumor of ovary Phase 2
- Salivary gland cancer Phase 2
- Salivary gland carcinoma Phase 2
Targets (1)
- AR Androgen Receptor antagonist